Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
28.00
-0.88 (-3.05%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Oruka Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
8.476.285.855.54.773.98
Upgrade
Research & Development
0.661.014.7513.834.991.83
Upgrade
Operating Expenses
9.137.310.619.349.775.81
Upgrade
Operating Income
-9.13-7.3-10.6-19.34-9.77-5.81
Upgrade
Interest Expense / Income
00000.010.01
Upgrade
Other Expense / Income
-1.93-1.96-0.67-0.01-0.03-0.17
Upgrade
Pretax Income
-7.2-5.34-9.93-19.32-9.75-5.65
Upgrade
Income Tax
0000-0.01-0.17
Upgrade
Net Income
-7.2-5.34-9.93-19.32-9.74-5.48
Upgrade
Shares Outstanding (Basic)
111100
Upgrade
Shares Outstanding (Diluted)
111100
Upgrade
Shares Change
0.67%0.04%3.64%195.18%256.50%71.72%
Upgrade
EPS (Basic)
-6.00-4.44-8.28-16.68-24.84-49.80
Upgrade
EPS (Diluted)
-6.00-4.44-8.28-16.68-24.84-49.80
Upgrade
Free Cash Flow
-6.89-5.01-10.91-18.81-7.74-4.81
Upgrade
Free Cash Flow Per Share
-5.70-4.17-9.09-16.23-19.73-43.64
Upgrade
EBITDA
-7.12-5.23-9.81-19.23-9.65-5.55
Upgrade
Depreciation & Amortization
0.080.110.110.090.090.09
Upgrade
EBIT
-7.2-5.34-9.93-19.32-9.74-5.64
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).